Cargando…

Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS

BACKGROUND: Health-related quality of life (HRQOL) outcomes are often included as secondary outcomes in clinical trials in secondary progressive MS (SPMS), but little is known about the longitudinal association of HRQOL and clinical and imaging outcome measures in SPMS. OBJECTIVE: To assess the asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	W Koch, Marcus, Mostert, Jop, Repovic, Pavle, Bowen, James D, Strijbis, Eva, Uitdehaag, Bernard, Cutter, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189721/ https://www.ncbi.nlm.nih.gov/pubmed/34965774 http://dx.doi.org/10.1177/13524585211063623

Ejemplares similares

The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials
por: Strijbis, Eva MM, et al.
Publicado: (2022)

MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis
por: Koch, Marcus W, et al.
Publicado: (2021)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

A comparison of clinical outcomes in PPMS in the INFORMS original trial data set
por: Koch, Marcus W, et al.
Publicado: (2021)

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
por: Strijbis, EMM, et al.
Publicado: (2023)

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set
por: Koch, Marcus W., et al.
Publicado: (2017)

COVID-19 in MS: Initial observations from the Pacific Northwest
por: Bowen, James D., et al.
Publicado: (2020)

Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS
por: Schoonhoven, Deborah N, et al.
Publicado: (2018)

Tremor in multiple sclerosis
por: Koch, Marcus, et al.
Publicado: (2007)

Repair what is lost: Neuroprotection through neural stem cells in progressive MS
por: Schoonheim, Menno M., et al.
Publicado: (2023)

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study
por: Wundes, Annette, et al.
Publicado: (2021)

Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19
por: Shin, Robert K., et al.
Publicado: (2022)

Anxiety is more important than depression in MS – Commentary
por: de Jong, Brigit A, et al.
Publicado: (2018)

The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial
por: Mostert, Jop, et al.
Publicado: (2013)

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial
por: Chan, Dennis, et al.
Publicado: (2017)

Adipokines in multiple sclerosis patients are related to clinical and radiological measures
por: Loonstra, Floor C., et al.
Publicado: (2022)

Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years
por: van der Linden, Femke AH, et al.
Publicado: (2008)

Is MS affecting the CNS only?: Lessons from clinic to myelin pathophysiology
por: Oudejans, Ellen, et al.
Publicado: (2020)

Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis
por: Lam, Ka-Hoo, et al.
Publicado: (2023)

Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
por: Uitdehaag, Bernard M. J.
Publicado: (2018)

Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life
por: Boscoe, Audra N., et al.
Publicado: (2019)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

The role of diet in multiple sclerosis onset and course: results from a nationwide retrospective birth‐year cohort
por: Loonstra, Floor C., et al.
Publicado: (2023)

Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS
por: Bittner, Frank, et al.
Publicado: (2017)

Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis
por: Balk, Lisanne J, et al.
Publicado: (2017)

Association of Arachidonic Acid–Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis
por: Broos, Jelle Y., et al.
Publicado: (2023)

Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis
por: Nauta, Ilse M, et al.
Publicado: (2020)

The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa
por: Cloosterman, Sonja, et al.
Publicado: (2021)

COVID-19 in multiple sclerosis: The Dutch experience
por: Loonstra, Floor C, et al.
Publicado: (2020)

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND
por: Repovic, Pavle, et al.
Publicado: (2020)

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial
por: Spain, Rebecca, et al.
Publicado: (2017)

Lipidomic UPLC-MS/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis
por: Pousinis, Petros, et al.
Publicado: (2020)

Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study
por: Zhang, Yinan, et al.
Publicado: (2021)

Outcome Measures in Clinical Trials for Multiple Sclerosis
por: van Munster, Caspar E. P., et al.
Publicado: (2017)

Factors affecting MS patients’ health-related quality of life and measurement challenges in Lebanon and the MENA region
por: Farran, Natali, et al.
Publicado: (2020)

Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis
por: O'Mahony, Julia, et al.
Publicado: (2022)

Aquatic training in MS: neurotherapeutic impact upon quality of life
por: Frohman, Ashley N, et al.
Publicado: (2015)

Health-related quality of life assessment in Indonesian childhood acute lymphoblastic leukemia
por: Sitaresmi, Mei N, et al.
Publicado: (2008)

Usability and Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using Depth-Sensing Computer Vision
por: Morrison, Cecily, et al.
Publicado: (2015)

Feasibility of “Sit Less, Move More”: An intervention for reducing sedentary behavior Among African Americans with MS
por: Baird, Jessica F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_13q7stcp0m0iiidq8qs351uakp